Lamotrigine
Small molecule targets HCN1 via activation
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | LAMICTAL ODT | — | 2015-05-18 | fda.gov ↗ |
| Label expansion | US (FDA) | LAMICTAL XR | — | 2011-04-25 | fda.gov ↗ |
| Label expansions (6) | US (FDA) | LAMICTAL CD | — | 1998-12-14 – 2006-09-22 | fda.gov ↗ |
| Label expansion | US (FDA) | LAMICTAL | — | 1998-08-24 | fda.gov ↗ |
| Approved | US (FDA) | LAMICTAL | — | 1994-12-27 | fda.gov ↗ |
Trials 106 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 119 trials | ||||||
| Phase 1 | NCT06729970 | Dec 2024 → Jan 2026 | — | Karuna Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04602221 | Dec 2020 → Aug 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04015687 | Jul → Oct 2019 | — | Agios Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03695094 | Sep 2018 → May 2019 | epilepsy | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 1 | NCT02513654 | Sep → Nov 2015 | bipolar disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02708849 | Jun 2015 → Mar 2020 | mental disorder | Yale University | Terminated | No outcome recorded |
| Phase 1 | NCT01888757 | Sep 2010 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT00907985 | May 2009 → Jun 2010 | bipolar disorder | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01607086 | Jul 2008 | mental disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00618241 | Feb → Oct 2008 | HIV infectious disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00410371 | Dec 2006 → Jan 2007 | mental disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02283801 | Nov 2006 → Jan 2007 | epilepsy | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1 | NCT00144872 | Nov 2004 → Apr 2006 | childhood absence epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00647751 | Aug 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00650208 | Jul → Aug 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00838136 | Feb → Mar 2002 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00838279 | Feb → Mar 2002 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00939458 | — | — | Torrent Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1 | NCT00939614 | — | — | Torrent Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02696512 | Mar 2016 → Mar 2017 | brain injury | International Brain Research Foundation | Unknown | No outcome recorded |
| Phase 1/2 | NCT00789113 | Nov 2008 → Jan 2011 | bipolar depression, epilepsy | University of Minnesota | Completed | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT04770493 | Jan 2022 → Oct 2023 | alcohol-related disorders | Brown University | Completed | No outcome recorded |
| Phase 2 | NCT03504501 | Mar 2019 → Feb 2023 | cognitive disorder, synaptopathy | Technical University of Munich | Terminated | No outcome recorded |
| Phase 2 | NCT03220256 | Aug 2016 → Aug 2018 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00917839 | Jun 2009 → Dec 2010 | relapsing-remitting multiple sclerosis | Cantonal Hospital of St. Gallen | Unknown | No outcome recorded |
| Phase 2 | NCT00269594 | Jan → Sep 2006 | neurotic disorder, obsessive-compulsive disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT00257855 | Nov 2005 → Jan 2009 | secondary progressive multiple sclerosis | University College London Hospitals | Completed | No outcome recorded |
| Phase 2 | NCT00176228 | Feb 2004 → Jan 2008 | bipolar disorder | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 2 | NCT00206778 | Jul 2003 → Jul 2007 | manic bipolar affective disorder | Beth Israel Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00044278 | Sep 2000 → Jun 2006 | epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00043875 | May 2000 → Nov 2003 | epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00015106 | Nov 1997 → Jan 1999 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00001482 | May 1995 → May 2001 | anxiety disorder, mood disorder, psychotic disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2 | NCT00000192 | Jan 1993 → Jan 1998 | substance-related disorder | Yale University | Withdrawn | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT02556060 | Sep 2015 → May 2017 | substance dependence | Taipei City Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02256124 | Oct 2014 → Apr 2020 | neurofibromatosis type 1 | Erasmus Medical Center | Terminated | No outcome recorded |
| Phase 2/3 | NCT00913107 | Sep 2007 → Feb 2008 | trigeminal neuralgia | University of Malaya | Completed | No outcome recorded |
| Phase 326 trials | ||||||
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT01602510 | Aug 2012 → Dec 2015 | bipolar I disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00571246 | Jun 2012 → Jun 2016 | alcohol dependence, post-traumatic stress disorder | Yale University | Withdrawn | No outcome recorded |
| Phase 3 | NCT01431976 | Sep 2011 → Feb 2014 | epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01431963 | Sep 2011 → Mar 2013 | epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00723450 | Jul 2008 → Aug 2013 | bipolar disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00566020 | May 2008 → Oct 2010 | bipolar I disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00621842 | Jan 2008 → Mar 2010 | bipolar depression | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00579982 | Jan → Feb 2008 | mood disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00516139 | Aug 2007 → Jul 2010 | epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00395694 | Aug 2006 → Mar 2009 | epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00355082 | May 2006 → Nov 2008 | focal epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00277641 | Mar 2006 → Jan 2009 | binge eating disorder, obesity disorder | Lindner Center of HOPE | Completed | No outcome recorded |
| Phase 3 | NCT00264615 | Oct 2005 → Jun 2006 | epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00104416 | Dec 2004 → Jul 2008 | epilepsy with generalized tonic-clonic seizures | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00113165 | Oct 2004 → Jul 2007 | focal epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00086593 | May 2004 → Jul 2005 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00068445 | Feb 2004 → May 2006 | chemotherapy-induced toxicity | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00071747 | Aug 2003 → Jan 2005 | schizophrenia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00266149 | Jun 2003 → May 2005 | epilepsy | University of Aarhus | Terminated | No outcome recorded |
| Phase 3 | NCT00074776 | May 2003 → Oct 2007 | bipolar disorder | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT00056277 | Feb 2003 → Aug 2005 | bipolar disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00224510 | Aug 2002 → Sep 2006 | bipolar depression | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00063362 | Feb 2002 → Jul 2007 | bipolar disorder | University Hospitals Cleveland Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT00226135 | Mar 2001 → Dec 2006 | bipolar disorder | University of Aarhus | Completed | No outcome recorded |
| Phase 3 | NCT00007670 | Jan 1998 → Mar 2003 | epilepsy | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 428 trials | ||||||
| Phase 4 | NCT05881928 | Jul 2024 overdue | epilepsy | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03689114 | May 2021 → Jun 2024 | focal epilepsy | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 4 | NCT03161509 | Jul 2017 → Dec 2018 | — | Rambam Health Care Campus | Terminated | No outcome recorded |
| Phase 4 | NCT02303106 | Nov 2014 → Apr 2015 | — | Per Damkier | Completed | No outcome recorded |
| Phase 4 | NCT02100644 | Apr 2014 → May 2015 | epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01713777 | Apr 2013 → Sep 2015 | epilepsy | University of Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT01733394 | Dec 2012 → Sep 2016 | epilepsy | University of Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT02429596 | May 2012 → May 2015 | epilepsy | IRCCS National Neurological Institute "C. Mondino" Foundation | Unknown | No outcome recorded |
| Phase 4 | NCT01015586 | Feb 2010 → May 2014 | alcohol dependence, depressive disorder, manic bipolar affective disorder, psychotic disorder | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 4 | NCT00807989 | Mar 2008 → May 2012 | epilepsy | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01000402 | Feb 2008 → Oct 2012 | attention deficit-hyperactivity disorder, bipolar disorder | Federal University of Rio Grande do Sul | Unknown | No outcome recorded |
| Phase 4 | NCT00855738 | May 2007 → Jun 2009 | focal epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00419003 | Dec 2006 → Jul 2008 | major depressive disorder | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00896987 | May 2006 → Dec 2008 | epilepsy | Korean Epilepsy Society | Completed | No outcome recorded |
| Phase 4 | NCT00360126 | Oct 2005 → Feb 2007 | bipolar disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00223509 | Aug 2005 → Nov 2007 | bipolar disorder | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT00181844 | Jan 2005 → Feb 2008 | manic bipolar affective disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00947375 | Jan 2005 → Jan 2006 | schizophrenia | Central Mental Clinic for Outpatients of Baku City | Terminated | No outcome recorded |
| Phase 4 | NCT00137709 | Nov 2004 → Jul 2008 | epilepsy | Chinese University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT00485771 | Nov 2003 → Jan 2005 | bipolar disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT02989727 | Nov 2003 → Aug 2005 | bipolar depression, melancholia | University of Saskatchewan | Completed | No outcome recorded |
| Phase 4 | NCT00067938 | Aug 2003 → Aug 2004 | bipolar disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00153244 | Aug 2002 → May 2003 | asthma | Centre of Chinese Medicine, Georgia | Completed | No outcome recorded |
| Phase 4 | NCT00223262 | Aug 2002 → Sep 2005 | brain disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00043914 | Jan 2002 → Jan 2003 | epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00188643 | Jan 2002 → Jan 2007 | bipolar disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 4 | NCT00177567 | Jul 2001 → Jan 2004 | bipolar disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00043901 | Dec 2000 → Nov 2003 | epilepsy with generalized tonic-clonic seizures | GlaxoSmithKline | Completed | No outcome recorded |
| Phase not applicable14 trials | ||||||
| — | NCT04939675 | Jul 2021 → Jun 2023 | epilepsy | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT04156035 | Mar → Dec 2020 | — | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT04396938 | May 2017 → Nov 2018 | — | University of Oxford | Completed | No outcome recorded |
| — | NCT05236166 | Apr 2017 → May 2021 | epilepsy | University Magna Graecia | Completed | No outcome recorded |
| — | NCT02556320 | May 2013 → Aug 2015 | drug allergy, epilepsy | University Hospital, Rouen | Completed | No outcome recorded |
| — | NCT01880957 | Nov 2011 → Jun 2017 | bipolar depression, major depressive disorder | Stony Brook University | Completed | No outcome recorded |
| — | NCT01463111 | May 2011 → Apr 2016 | bipolar disorder | Emory University | Completed | No outcome recorded |
| — | NCT00531518 | Oct 2007 → May 2013 | bipolar disorder, depressive disorder, schizophrenia | MaineHealth | Completed | No outcome recorded |
| — | NCT00720473 | Apr 2006 → Jul 2011 | bipolar depression | Mclean Hospital | Completed | No outcome recorded |
| — | NCT00284791 | Jan 2006 → Feb 2007 | — | MaineHealth | Terminated | No outcome recorded |
| — | NCT00901407 | Dec 2003 → Jul 2006 | major depressive disorder | Louisiana State University Health Sciences Center in New Orleans | Completed | No outcome recorded |
| — | NCT00208520 | Jul 2003 → Jun 2007 | epilepsy syndrome | Dutch Epilepsy Clinics Foundation | Unknown | No outcome recorded |
| — | NCT00012558 | Sep 1998 → Sep 2005 | bipolar disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| — | NCT00241995 | — | — | St. Petersburg State Pavlov Medical University | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03419949 | — | — | Assiut University | Available | No outcome recorded |
Also used as a comparator or background therapy in 49 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05145608 Comparator | Jan → Feb 2018 | — | Alembic Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02707965 Comparator | Jun 2017 → Aug 2018 | epilepsy | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT02821338 Comparator | Jun → Sep 2016 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT02081287 Comparator | May 2014 → Jul 2018 | manic bipolar affective disorder | San Diego Veterans Healthcare System | Completed | No outcome recorded |
| Phase 1 | NCT00627575 Comparator | Feb → Sep 2008 | epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05420350 Comparator | Dec 2020 → Jul 2024 | Meniere disease | Dent Neuroscience Research Center | Unknown | No outcome recorded |
| Phase 2 | NCT02158585 Comparator | Jun 2014 → Mar 2017 | Meniere disease | Dent Neuroscience Research Center | Completed | No outcome recorded |
| Phase 2 | NCT01674010 Background | Aug 2012 → Jun 2014 | bipolar I disorder | OPKO Health, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00475137 Comparator | Dec 2007 → Jun 2015 | bipolar II disorder | University of British Columbia | Completed | No outcome recorded |
| Phase 2 | NCT00513019 Comparator | Aug 2007 → Aug 2009 | neurotic excoriation | University of Chicago | Completed | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT06929273 Background | Jul 2025 → Jun 2028 expected | bipolar I disorder | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 3 | NCT05017155 Comparator | Aug 2021 → Aug 2023 | nondystrophic myotonia | University College, London | Unknown | No outcome recorded |
| Phase 3 | NCT04274179 Comparator | Aug 2020 → May 2028 expected | childhood absence epilepsy | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 3 | NCT03831854 Comparator | Jan 2019 → Dec 2020 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 3 | NCT01939561 Comparator | Nov 2013 → Nov 2015 | hyperkalemic periodic paralysis, myotonic dystrophy type 1, paramyotonia congenita of Von Eulenburg, potassium-aggravated myotonia | Grete Andersen, MD | Completed | No outcome recorded |
| Phase 3 | NCT01891890 Comparator | Aug 2013 → Oct 2015 | focal epilepsy | Emory University | Terminated | No outcome recorded |
| Phase 3 | NCT01042496 Comparator | Dec 2009 → Sep 2014 | bipolar depression | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00550407 Comparator | Nov 2007 → Oct 2009 | bipolar disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00280059 Comparator | Aug 2006 → Dec 2009 | focal epilepsy | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00292461 Comparator | Mar 2006 → Aug 2009 | epilepsy | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00242606 Comparator | Mar 2005 → Jun 2008 | epilepsy | Philipps University Marburg | Completed | No outcome recorded |
| Phase 3 | NCT00088452 Comparator | Jul 2004 → Jan 2013 | childhood absence epilepsy | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 3 | NCT00652171 Comparator | Jan 2004 → Jan 2006 | depressive disorder | Institute of Social Security of the Civil Servants of Minas Gerais | Completed | No outcome recorded |
| Phase 3 | NCT00274677 Comparator | Nov 2003 → Aug 2005 | bipolar disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00221975 Comparator | Jul 2002 → Jun 2007 | bipolar disorder | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 418 trials | ||||||
| Phase 4 | NCT06184581 Comparator | May 2024 → Dec 2027 expected | bipolar II disorder | University Hospital Bispebjerg and Frederiksberg | Recruiting | No outcome recorded |
| Phase 4 | NCT05697614 Comparator | Mar → May 2023 | epilepsy | Dr Cipto Mangunkusumo General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05748236 Comparator | Nov 2022 → Oct 2023 | focal epilepsy | Dhaka Medical College | Unknown | No outcome recorded |
| Phase 4 | NCT02670161 Comparator | May 2016 → Dec 2026 expected | Parkinson disease, brain neoplasm, cognitive impairment with or without cerebellar ataxia, epilepsy +6 | Endeavor Health | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT02404168 Comparator | Jul 2015 → Jan 2016 | epilepsy | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT02389712 Comparator | Mar 2015 → May 2018 | bipolar disorder | Mayo Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT02205931 Comparator | Jan 2015 → Jun 2018 | epilepsy | University College, London | Unknown | No outcome recorded |
| Phase 4 | NCT01588457 Comparator | Jun 2011 → Dec 2016 | bipolar I disorder, bipolar II disorder | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT01142310 Comparator | Jun 2010 → Jun 2015 | cognitive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00926835 Comparator | May 2009 → May 2015 | major depressive disorder | Ministry of Health & Welfare, Korea | Terminated | No outcome recorded |
| Phase 4 | NCT01864551 Comparator | Aug 2008 → Jul 2009 | bipolar disorder | Tri-Service General Hospital (TSGH) | Completed | No outcome recorded |
| Phase 4 | NCT00552526 Comparator | Nov 2007 → Jan 2011 | epilepsy | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00438451 Comparator | Jan 2007 → Jul 2010 | focal epilepsy | Johannes Gutenberg University Mainz | Completed | No outcome recorded |
| Phase 4 | NCT00280293 Comparator | Mar 2006 → Jan 2010 | bipolar disorder, cocaine dependence | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04523935 Comparator | Dec 2005 → Aug 2020 | cerebral palsy | Sathbhavana Brain Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00277212 Background | Dec 2005 → Jul 2009 | bipolar disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00634062 Comparator | Dec 2004 → Sep 2007 | borderline personality disorder | Mclean Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00183469 Comparator | Dec 2004 → Feb 2009 | bipolar disorder, depressive disorder | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT05639257 Comparator | Dec 2022 → Apr 2024 | nondystrophic myotonia | Grete Andersen, MD | Unknown | No outcome recorded |
| — | NCT03636958 Background | Feb 2021 → Jul 2025 | epilepsy | Assistance Publique Hopitaux De Marseille | Withdrawn | No outcome recorded |
| — | NCT02300051 Background | Feb 2011 → Apr 2015 | sexual disorder | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| — | NCT00916149 Comparator | Jan 2007 → Oct 2012 | epilepsy | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT00243152 Comparator | Oct 2005 → Jul 2008 | facial neuralgia | Pain and Analgesia Imaging and Neuroscience Group | Completed | No outcome recorded |
| — | NCT00203229 Comparator | Jun 2003 → May 2006 | trigeminal neuralgia | Thomas Jefferson University | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2008-07-23 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Introduces First Generic Lamictal® Tablets in the United States tevapharm.com ↗ |
| 2005-02-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Settlement Of Lamictal® Litigation With Glaxosmithkline tevapharm.com ↗ |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 161 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lamotrigine | “Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate,...” NCT00552526 ↗151“Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12,...” NCT02696512 ↗ “Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin,...” NCT03636958 ↗ “In this study, we evaluated the efficacy and occurrence of side effects of lamotrigine (LTG) in comparison with carbamazepine (CBZ), in trigeminal neuralgia (TN) patients.” PMID 21621166 ↗ May 2011 “The study is aimed to evaluate the efficacy of antiglutamate anticonvulsants (topiramate, lamotrigine, and memantine) in the treatment of alcohol withdrawal syndrome” NCT00241995 ↗ “Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)” NCT02556320 ↗ “This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of partial seizures.” NCT00113165 ↗ “mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).” NCT02300051 ↗ “Lamotrigine monotherapy for newly diagnosed typical absence seizures in children: A multi-center, uncontrolled, open-label study.” PMID 26518979 ↗ Oct 2015 “Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide” NCT05236166 ↗ “The purpose of this study is to determine the effect of lamotrigine augmentation of Haloperidol decanoate” NCT00947375 ↗ “carbamazepine, valproic acid, topiramate, oxcarbazepine, levetiracetam or lamotrigine” NCT02429596 ↗ “Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy” NCT01431963 ↗ “Lamotrigine (according to response, and tolerance)25-200mg” NCT01000402 ↗ “brain tumors (lamotrigine, levetiracetam, valproic acid)” NCT02670161 ↗ “Ethosuximide, valproate or lamotrigine” NCT04274179 ↗ “Lamictal (lamotrigine)” NCT00269594 ↗ “Lamotrigine” NCT02205931 ↗ |
| Known as | 430C78 | “The objective of this sensory analysis study is to determine whether volunteers observe a significant difference in organoleptic properties between lamotrigine (430C78) cherry...” NCT01607086 ↗ |
| Known as | BW430C | “BW430C (lamotrigine)” NCT00566020 ↗ |
| Known as | Lamictal | “The objective of this study was to investigate the bioequivalence of Mylan's lamotrigine 25 mg tablets to GlaxoSmithKline's (GSK) Lamictal® 25 mg tablets following a single,...” NCT00650208 ↗19“This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of...” NCT00044278 ↗ “The aim of this project is to evaluate the effects of the anticonvulsant drug lamotrigine (trade name Lamictal) on neuropathic facial pain or neuralgia using functional...” NCT00243152 ↗ “Baclofen(Liofen®),Diazepam,(Valium®),Clonazepam,(Klonopin®),Trihexyphenidyl(Artane®),Tetrabenazine(Xenazine®),Gabapentin(Neurontin®),Topiramate(Topamax®),Lamotrigine(Lamictal®),...” NCT04523935 ↗ “A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed...” NCT00280059 ↗ “A Multicentre, Double-Blind, Randomised, Fixed-Dose Evaluation of the Safety and Efficacy of Lamotrigine (Lamictal) compared to placebo as add-on therapy to lithium” NCT00224510 ↗ “switched from your regular lamotrigine (Lamictal®) to once daily morning dosing of an extended-release formulation of Lamictal-XR® (at the same total daily dose).” NCT00789113 ↗ “This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of partial seizures.” NCT00113165 ↗ “The study drug Lamictal® (lamotrigine) and both of the generic forms of lamotrigine to be tested are approved by the FDA for the treatment of seizures.” NCT01733394 ↗ “This study will compare the medications lithium and lamotrigine (Lamictal®) in treating depression in individuals with bipolar II disorder.” NCT00074776 ↗ “Lamotrigine (Lamictal®) recently gained approval by the FDA for maintenance treatment of bipolar disorder in adults.” NCT00284791 ↗ “Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA” NCT00939458 ↗ “Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal).” NCT00181844 ↗ “Lamictal® (Lamotrigine) 2×25 mg Tablets of GlaxoSmithKline, USA” NCT00939614 ↗ “Lamictal® was used as the "active" medication in this study.” NCT00913107 ↗ “lamotrigine (LAMICTAL) extended-release” NCT00104416 ↗ |
| Known as | Lamictal (Registered Trademark) | “Lamotrigine (Lamictal® (Registered Trademark)” NCT00001482 ↗ |
| Known as | Lamictal cd | ChEMBL registry synonym — accepted as the source's own label CHEMBL741 ↗ |
| Known as | Lamictal odt | ChEMBL registry synonym — accepted as the source's own label CHEMBL741 ↗ |
| Known as | Lamictal-XR | “switched from your regular lamotrigine (Lamictal®) to once daily morning dosing of an extended-release formulation of Lamictal-XR® (at the same total daily dose).” NCT00789113 ↗ |
| Known as | Lamotrigina | ChEMBL registry synonym — accepted as the source's own label CHEMBL741 ↗ |
| Known as | Lamotrigine (generic name for Lamictal) | “Lamotrigine (generic name for Lamictal®)” NCT00913107 ↗ |
| Known as | Lamotrigine Generic "A" | “Drug: Lamotrigine Generic "A"” NCT01713777 ↗ |
| Known as | Lamotrigine generic "B" | “Drug: Lamotrigine generic "B"” NCT01713777 ↗ |
| Known as | LTG | “To evaluate the tolerability and efficacy of levetiracetam (LEV) in newly diagnosed elderly patients (aged 60 yrs or above) with focal epilepsy compared to lamotrigine (LTG) or...” NCT00438451 ↗9“Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once...” NCT02100644 ↗ “In animal studies, pathway-specific pharmacological interventions with lovastatin (LOV) and lamotrigine (LTG) have been shown to improve synaptic plasticity as well as...” PMID 37280688 ↗ Jun 2023 “PURPOSE: To evaluate the efficacy and safety of lamotrigine (LTG) monotherapy for treating Japanese and South Korean pediatric patients with newly diagnosed typical absence seizures.” PMID 26518979 ↗ Oct 2015 “This is an open-label study evaluating the efficacy and safety of lamotrigine (LTG) for the treatment of newly-diagnosed typical absence seizures.” NCT00144872 ↗ “The objective of this study was to compare lamotrigine (LTG) and lithium (Li) monotherapy for the treatment of BDII depression.” PMID 18358540 ↗ Mar 2008 “This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy.” NCT00516139 ↗ “Lamotrigine (LTG) is a second generation AED , and also has the function of resisting depression and stabilizing mood .” NCT05881928 ↗ “example anti epilepsy drug (AED) used for this study will be lamotrigine (LTG).” NCT01733394 ↗ “lamotrigine (LTG)” PMID 22595362 ↗ May 2012 |
| Known as | NSC-759171 | ChEMBL registry synonym — accepted as the source's own label CHEMBL741 ↗ |
| Known as | Reference- Lamictal XRTM (Lamotrigine) ER tablet 50mg | “Reference- Lamictal® XRTM (Lamotrigine) ER tablet 50mg” NCT05145608 ↗ |
| Action | Inhibit | “Lamotrigine, a phenyltriazine use-dependent sodium channel blocker that inhibits release of excitatory amino acids” NCT00001482 ↗ |
| Modality | Small molecule | — CHEMBL741 ↗ |
| Route | Oral | “Patients receive oral lamotrigine once daily for 2 weeks and then twice daily for 8 weeks.” NCT00068445 ↗ |
| Target | HCN1 | “Lamotrigine, an HCN1-agonist, rescued this electrophysiological phenotype in an NF1 mouse model.” PMID 40121838 ↗ Mar 2025 |